
WideTrial Closes Enrollment for ALS Expanded Access Program
Two hundred patients across 27 states have joined the SEANOBI-ALS program, reaching the study's enrollment capacity in under 13 months. The initiative provides the investigational drug MN-166, also known as ibudilast, to individuals who remain ineligible for traditional clinical trials due to strict entry criteria or geographic barriers.






















